Article Information
History
- April 1, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Nayan Lamba, M.D.1,2,
- Malia McAvoy, M.S.3,4,
- Vasileios K. Kavouridis, M.D., M.P.H.4,5,
- Timothy R. Smith, M.D., Ph.D., M.P.H.3,4,
- Mehdi Touat, M.D.6,7,
- David A. Reardon, M.D.3,8 and
- J. Bryan Iorgulescu, M.D.3,4,9,10,*
- 1Department of Radiation Oncology, Brigham and Women’s Hospital, Boston, MA
- 2Department of Medicine, Cambridge Health Alliance, Cambridge, MA
- 3Harvard Medical School, Boston, MA
- 4Computational Neuroscience Outcomes Center, Department of Neurosurgery, Brigham and Women’s Hospital, Boston, MA
- 5Department of Surgery, St. Elizabeth’s Medical Center, Brighton, MA
- 6Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA
- 7Sorbonne Université; Institut du Cerveau et de la Moelle épinière; Service de Neurologie, Hôpitaux Universitaires La Pitié Salpêtrière, Paris, France
- 8Center for Neuro-Oncology, Department of Medical Oncology, Dana-Farber Cancer Center, Boston, MA
- 9Department of Pathology, Brigham and Women’s Hospital, Boston, MA
- 10Department of Medical Oncology, Dana-Farber Cancer Institute, Boston MA
- ↵*Corresponding author:
J. Bryan Iorgulescu, M.D., Department of Pathology, Brigham and Women’s Hospital, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 75 Francis St., Boston, MA 02115, Phone: 617-732-7510, Fax: 617-277-9015, jiorgulescu{at}bwh.harvard.edu
Posted April 01, 2020.
Short-term outcomes associated with temozolomide vs. PCV chemotherapy for 1p/19q-codeleted WHO grade III anaplastic oligodendrogliomas: a national evaluation
